These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 31150059)

  • 1. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
    Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
    Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
    Bedikian AY; Legha SS; Mavligit G; Carrasco CH; Khorana S; Plager C; Papadopoulos N; Benjamin RS
    Cancer; 1995 Nov; 76(9):1665-70. PubMed ID: 8635073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
    Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM
    Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
    Korn EL; Liu PY; Lee SJ; Chapman JA; Niedzwiecki D; Suman VJ; Moon J; Sondak VK; Atkins MB; Eisenhauer EA; Parulekar W; Markovic SN; Saxman S; Kirkwood JM
    J Clin Oncol; 2008 Feb; 26(4):527-34. PubMed ID: 18235113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactate Dehydrogenase Prior to Transarterial Hepatic Chemoperfusion Predicts Survival and Time to Progression in Patients with Uveal Melanoma Liver Metastases.
    Ludwig J; Haubold J; Heusner TA; Bauer S; Siveke JT; Richly H; Wetter A; Umutlu L; Theysohn JM
    Rofo; 2021 Jun; 193(6):683-691. PubMed ID: 33348383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
    Leyvraz S; Piperno-Neumann S; Suciu S; Baurain JF; Zdzienicki M; Testori A; Marshall E; Scheulen M; Jouary T; Negrier S; Vermorken JB; Kaempgen E; Durando X; Schadendorf D; Gurunath RK; Keilholz U
    Ann Oncol; 2014 Mar; 25(3):742-746. PubMed ID: 24510314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
    Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
    J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea.
    Gonsalves CF; Eschelman DJ; Thornburg B; Frangos A; Sato T
    AJR Am J Roentgenol; 2015 Aug; 205(2):429-33. PubMed ID: 25905562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic model and staging for metastatic uveal melanoma.
    Eskelin S; Pyrhönen S; Hahka-Kemppinen M; Tuomaala S; Kivelä T
    Cancer; 2003 Jan; 97(2):465-75. PubMed ID: 12518371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion.
    Ludwig JM; Haubold J; Bauer S; Richly H; Siveke JT; Wimmer J; Umutlu L; Schaarschmidt BM; Theysohn JM
    Radiol Oncol; 2021 May; 55(3):347-353. PubMed ID: 34051707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
    Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
    Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome.
    Schuster R; Lindner M; Wacker F; Krössin M; Bechrakis N; Foerster MH; Thiel E; Keilholz U; Schmittel A
    Melanoma Res; 2010 Jun; 20(3):191-6. PubMed ID: 20335820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.
    Eldredge-Hindy H; Ohri N; Anne PR; Eschelman D; Gonsalves C; Intenzo C; Bar-Ad V; Dicker A; Doyle L; Li J; Sato T
    Am J Clin Oncol; 2016 Apr; 39(2):189-95. PubMed ID: 24441583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of sunitinib malate in patients with metastatic uveal melanoma.
    Mahipal A; Tijani L; Chan K; Laudadio M; Mastrangelo MJ; Sato T
    Melanoma Res; 2012 Dec; 22(6):440-6. PubMed ID: 23114504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
    Zager JS; Orloff M; Ferrucci PF; Choi J; Eschelman DJ; Glazer ES; Ejaz A; Howard JH; Richtig E; Ochsenreither S; Reddy SA; Lowe MC; Beasley GM; Gesierich A; Bender A; Gschnell M; Dummer R; Rivoire M; Arance A; Fenwick SW; Sacco JJ; Haferkamp S; Weishaupt C; John J; Wheater M; Ottensmeier CH
    Ann Surg Oncol; 2024 Aug; 31(8):5340-5351. PubMed ID: 38704501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
    Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G
    Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
    Alexander M; Mellor JD; McArthur G; Kee D
    Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
    Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
    Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.